Discovery Lens
C Combination Innovation
Two separate worlds finally connect — and the intersection is a product
In Plain English
Brazil has 12,000 Catholic parishes with 30,000+ trained lay health agents who visit rural homes and check on sick residents. These agents have no connection to telehealth — if a patient needs a doctor, the agent fills out a paper form and refers them to the public health system where the wait is 30-90 days. This tool would give lay agents a phone app to connect patients to a doctor during the home visit, funded by Misereor (a German Catholic charity with EUR 200M+ annual budget that specifically funds Brazilian Catholic health programs). The idea is real — the distribution channel is real, the pain is real — but the monetization depends on multi-year charity grants that are not compatible with venture growth timelines.
One-Liner
Telehealth platform distributed through Brazil's Catholic parish lay-health-agent network, funded via Misereor and CNBB diocesan grant programs to serve rural Brazilians who face 30-90 day SUS specialist wait times.
AI Thinking Process
Cross-domain: religious distribution networks × consumer telehealth. Brazil has 12,000+ Catholic parishes with 30K+ lay health agents (Pastoral da Saúde). ConexaSaúde and Sami have never approached this channel. No formal church-telehealth partnership exists.
G134 distribution community: Pastoral da Saúde has 30K+ trained lay health agents across Brazilian dioceses. ✓ G151 check: Does Pastoral da Saúde have its own internal telehealth product? No — runs in-person education and home visits only. G151 does NOT fire.
G144 buyer-budget test: (1) parishioner cannot pay $10/month ✓. (2) diocese budgets too small ✓. (3) third-party advocate has budget: Misereor EUR 200M+ annual program budget funds Brazilian Catholic health programs. G144 OFFSET by Misereor.
Survived at 41% conviction. Biggest worry: Catholic church procurement (years), founder profile (Portuguese-fluent, Brazil-resident, theologically credible), Misereor grant cycles not venture-compatible.
Brazil 12,000 parishes confirmed (CNBB reports 11,000-12,500). Pastoral da Saúde 30K+ lay agents confirmed directionally (combined Pastoral da Saúde + Pastoral da Criança = 50K+). Misereor EUR 200M+ confirmed. SUS 30-90 day wait confirmed (Ministry of Health data). ConexaSaúde $50M+ confirmed.
structural adoption barrier is partially present: parishes may resist telehealth that appears to replace in-person lay-agent visits. Lay agents are community organizers, not just health workers — the visit itself is the community function. Reframing as 'empowers the lay agent during the visit' mitigates but does not eliminate this.
Conviction revised: 41% → 39%. 2-point drop for partial structural adoption barrier and Misereor grant cycle incompatibility with venture timelines. Falls below 40% crossdomain floor.
Downgraded to COLD in Pass 3. Kill mechanism: r5_monetization = 0.28 triggers hard gate. Misereor grants are 2-3 year programs, not SaaS cash flow. No per-user revenue model is viable for low-income rural Brazilians. Kill is not positional — the distribution channel is relational and irreplaceable, but the monetization model cannot become venture-scale without the same charitable funding that defines its ceiling.
The Surprising Insight
Brazil's Pastoral da Saúde runs 30,000+ lay health agents across 11,000-12,500 parishes with no telehealth integration — a distribution channel that ConexaSaúde ($50M+ raised) and Sami have never approached — but Misereor's 18-24 month grant cycles are not compatible with venture-scale growth expectations.
Kill Reason
Monetization depends on Misereor grant cycles (18-24 months, 2-3 year programs) which are not venture-scale cash flows; diocese budgets are too small for meaningful SaaS ACV; no per-user revenue model is viable when the end user is a low-income rural Brazilian. The distribution channel is real and the pain is real but the buyer cannot pay at venture scale.
AI Self-Correction
↓2pts — confidence dropped after deeper analysis
Risk Analysis
Outer edge = low risk · Center = high risk · Red = flagged dimension (≤ 0.35)
Adoption Barriers
Parish communities may resist if telehealth is positioned as replacing the in-person lay-agent home visit, which serves community-organizing purposes beyond health. Reframing as 'tool that empowers the lay agent during the visit' is plausible but untested. The partial structural adoption barrier reduces expected adoption rate.
Competitive Landscape
ConexaSaúde (Brazil, $50M+ raised) partners with corporates and health plans — has never approached parish channels. Sami (B2B2C primary care plan) is employer-channel only. Cáritas Brasileira runs Catholic social services including some health programs and is a channel-conflict risk if they enter telehealth directly. Pastoral da Criança (child health lay-agent network, separate from Pastoral da Saúde) could be a parallel partnership. No commercial telehealth has formally partnered with CNBB or Misereor. Gap is real but distribution channel is slow-moving and relational.
What do you think?
Related ideas you can explore free:
killed: Passive voice-based depression detection requires FDA Software as a Medical Device clearance for any diagnostic claim; a "wellness" framing undercuts the core value proposition and reduces willingness to pay. Epic Systems and large telehealth platforms are already integrating validated mental health screening tools into clinical workflows, crowding out standalone apps before they achieve scale.
killed: Google Nest Hub's built-in Soli radar-based sleep sensing already delivers contactless respiratory monitoring in millions of households, and Withings has shipped FDA-cleared sleep apnea screening hardware. A standalone $30 WiFi module cannot match the distribution, brand trust, or regulatory standing of these well-resourced incumbents.
killed: Urine and stool analysis for glucose monitoring, cancer screening, and kidney function markers falls squarely into FDA Class II/III medical device territory, requiring clinical trials and 510(k) or PMA approval costing millions and taking years. The entire high-value use case — the reason anyone would buy this — is legally undeliverable without regulatory clearance the product cannot realistically obtain.